179 related articles for article (PubMed ID: 19551468)
1. NAP protects against cyanide-related microtubule destruction.
Zemlyak I; Sapolsky R; Gozes I
J Neural Transm (Vienna); 2009 Nov; 116(11):1411-6. PubMed ID: 19551468
[TBL] [Abstract][Full Text] [Related]
2. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection.
Gozes I; Divinski I
J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S37-41. PubMed ID: 15665412
[TBL] [Abstract][Full Text] [Related]
3. NAP protects hippocampal neurons against multiple toxins.
Zemlyak I; Manley N; Sapolsky R; Gozes I
Peptides; 2007 Oct; 28(10):2004-8. PubMed ID: 17869381
[TBL] [Abstract][Full Text] [Related]
4. NAP protects against cytochrome c release: inhibition of the initiation of apoptosis.
Zemlyak I; Sapolsky R; Gozes I
Eur J Pharmacol; 2009 Sep; 618(1-3):9-14. PubMed ID: 19619522
[TBL] [Abstract][Full Text] [Related]
5. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell.
Gozes I; Divinski I
Curr Alzheimer Res; 2007 Dec; 4(5):507-9. PubMed ID: 18220512
[TBL] [Abstract][Full Text] [Related]
6. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease.
Esteves AR; Gozes I; Cardoso SM
Biochim Biophys Acta; 2014 Jan; 1842(1):7-21. PubMed ID: 24120997
[TBL] [Abstract][Full Text] [Related]
7. Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide).
Gozes I; Iram T; Maryanovsky E; Arviv C; Rozenberg L; Schirer Y; Giladi E; Furman-Assaf S
J Alzheimers Dis; 2014; 40 Suppl 1():S23-36. PubMed ID: 24503616
[TBL] [Abstract][Full Text] [Related]
8. The neuroprotective peptide NAP does not directly affect polymerization or dynamics of reconstituted neural microtubules.
Yenjerla M; LaPointe NE; Lopus M; Cox C; Jordan MA; Feinstein SC; Wilson L
J Alzheimers Dis; 2010; 19(4):1377-86. PubMed ID: 20061604
[TBL] [Abstract][Full Text] [Related]
9. The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy.
Zemlyak I; Manley N; Vulih-Shultzman I; Cutler AB; Graber K; Sapolsky RM; Gozes I
J Neurochem; 2009 Dec; 111(5):1252-63. PubMed ID: 19799711
[TBL] [Abstract][Full Text] [Related]
10. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.
Shiryaev N; Pikman R; Giladi E; Gozes I
Curr Pharm Des; 2011; 17(25):2603-12. PubMed ID: 21728979
[TBL] [Abstract][Full Text] [Related]
11. Microtubule stabilization by peloruside A and paclitaxel rescues degenerating neurons from okadaic acid-induced tau phosphorylation.
Das V; Miller JH
Eur J Neurosci; 2012 Jun; 35(11):1705-17. PubMed ID: 22594877
[TBL] [Abstract][Full Text] [Related]
12. NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42).
Gozes I; Divinski I; Piltzer I
BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S3. PubMed ID: 19091000
[TBL] [Abstract][Full Text] [Related]
13. The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.
Oz S; Ivashko-Pachima Y; Gozes I
PLoS One; 2012; 7(12):e51458. PubMed ID: 23272107
[TBL] [Abstract][Full Text] [Related]
14. NAP alpha-aminoisobutyric acid (IsoNAP).
Gozes I; Schirer Y; Idan-Feldman A; David M; Furman-Assaf S
J Mol Neurosci; 2014 Jan; 52(1):1-9. PubMed ID: 24458740
[TBL] [Abstract][Full Text] [Related]
15. ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.
Ivashko-Pachima Y; Sayas CL; Malishkevich A; Gozes I
Mol Psychiatry; 2017 Sep; 22(9):1335-1344. PubMed ID: 28115743
[TBL] [Abstract][Full Text] [Related]
16. Involvement of calpain and p25 of CDK5 pathway in ginsenoside Rb1's attenuation of beta-amyloid peptide25-35-induced tau hyperphosphorylation in cortical neurons.
Chen X; Huang T; Zhang J; Song J; Chen L; Zhu Y
Brain Res; 2008 Mar; 1200():99-106. PubMed ID: 18289510
[TBL] [Abstract][Full Text] [Related]
17. {beta}-Amyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents.
Michaelis ML; Ansar S; Chen Y; Reiff ER; Seyb KI; Himes RH; Audus KL; Georg GI
J Pharmacol Exp Ther; 2005 Feb; 312(2):659-68. PubMed ID: 15375176
[TBL] [Abstract][Full Text] [Related]
18. Peptide neuroprotection through specific interaction with brain tubulin.
Divinski I; Holtser-Cochav M; Vulih-Schultzman I; Steingart RA; Gozes I
J Neurochem; 2006 Aug; 98(3):973-84. PubMed ID: 16893427
[TBL] [Abstract][Full Text] [Related]
19. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.
Shiryaev N; Jouroukhin Y; Giladi E; Polyzoidou E; Grigoriadis NC; Rosenmann H; Gozes I
Neurobiol Dis; 2009 May; 34(2):381-8. PubMed ID: 19264130
[TBL] [Abstract][Full Text] [Related]
20. Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).
Magen I; Gozes I
Neuropeptides; 2013 Dec; 47(6):489-95. PubMed ID: 24210139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
